[Resistance to rituximab and CD20 mutation].
Terui
Yasuhito
Y
Department of Medical Oncology/Hematology, The Cancer Institute Hospital of JFCR.
Hatake
Kiyohiko
K
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000235:genetics*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D009154:Mutation; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab